What is Northwest Bio's earnings per share (EPS)?

Northwest Bio (NWBO) reported diluted earnings per share of -$0.04 for fiscal year 2025. This represents a 42.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Northwest Bio Financials

NWBO

FY2025 annual

Revenue $1.4M -0.3% YoY

Net Income -$60.2M +28.2% YoY

EPS (Diluted) -$0.04 +42.9% YoY

Free Cash Flow -$46.3M +20.3% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Northwest Bio (NWBO) reported $1.4M in revenue for fiscal year 2025, down 0.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NWBO FY2025 2026-05-15

NWBO’s core mechanic is a capital-funded development model, where external financing rather than sales supports research and corporate overhead.

In FY2025, financing inflows of $49.3M nearly matched operating cash burn of $44.8M. With cash at only $3.0M, negative equity still present, and the share count still climbing, new capital appears to be replacing consumed cash rather than creating a liquidity cushion.

From FY2023 through FY2025, sales stayed tiny relative to the pre-scale cost structure, with R&D and SG&A together many times larger than revenue. The operating loss improved from $66.5M to $59.9M, but that looks like expense moderation rather than operating leverage from a larger revenue base.

FY2025 did not repair the balance sheet: liabilities were $128.9M against assets of $81.3M, leaving negative equity even after assets increased. With near-term obligations of $91.7M versus current assets of $5.5M, the company still appears dependent on outside capital to bridge everyday funding needs.

Financial Health Signals

Financial health score not available

Northwest Bio does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-28.20

Northwest Bio scores -28.20, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($296.6M) relative to total liabilities ($128.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Northwest Bio passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Northwest Bio reported a net loss of $60.2M while operations used $44.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Northwest Bio reported an operating loss of $59.9M against $8.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.4M

YoY-0.3%

5Y CAGR+1.3%

10Y CAGR-2.3%

Northwest Bio generated $1.4M in revenue in fiscal year 2025. This represents a decrease of 0.3% from the prior year.

EBITDA

-$57.9M

YoY+10.7%

Northwest Bio's EBITDA was -$57.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.7% from the prior year.

Net Income

-$60.2M

YoY+28.2%

Northwest Bio reported -$60.2M in net income in fiscal year 2025. This represents an increase of 28.2% from the prior year.

EPS (Diluted)

-$0.04

YoY+42.9%

Northwest Bio earned -$0.04 per diluted share (EPS) in fiscal year 2025. This represents an increase of 42.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$46.3M

YoY+20.3%

Northwest Bio recorded an outflow of $46.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 20.3% from the prior year.

Cash & Debt

$3.0M

YoY+39.8%

5Y CAGR-21.2%

10Y CAGR-17.9%

Northwest Bio held $3.0M in cash against $60.0M in long-term debt as of fiscal year 2025.

Shares Outstanding

1.56B

YoY+17.1%

5Y CAGR+13.6%

Northwest Bio had 1.56B shares outstanding in fiscal year 2025. This represents an increase of 17.1% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$28.8M

YoY-17.5%

5Y CAGR-3.1%

10Y CAGR-12.0%

Northwest Bio invested $28.8M in research and development in fiscal year 2025. This represents a decrease of 17.5% from the prior year.

Capital Expenditures

$1.5M

YoY+48.3%

Northwest Bio invested $1.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 48.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

NWBO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NWBO annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$2.2M	$1.4M-0.3%	$1.4M-28.5%	$1.9M+14.8%	$1.7M+67.5%	$1.0M-22.2%	$1.3M-46.4%	$2.4M+485.0%	$412K+22.6%	$336K-46.1%	$623K-64.2%	$1.7M+19.6%	$1.5M+79.7%	$809K+4.8%	$772K+7620.0%	$10K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$809K+4.8%	$772K+7620.0%	$10K
R&D Expenses	$23.6M	$28.8M-17.5%	$34.9M+25.8%	$27.7M-21.9%	$35.5M+74.9%	$20.3M-39.6%	$33.6M+138.5%	$14.1M-22.3%	$18.2M-45.8%	$33.5M-44.2%	$60.1M-41.7%	$103.1M+20.4%	$85.6M+95.0%	$43.9M+51.9%	$28.9M	N/A
SG&A Expenses	$28.9M	$32.5M-1.5%	$33.0M+11.1%	$29.7M-10.9%	$33.4M-0.1%	$33.4M-38.4%	$54.3M+233.2%	$16.3M-27.7%	$22.5M+80.7%	$12.5M+14.6%	$10.9M-40.7%	$18.3M+8.1%	$17.0M+37.0%	$12.4M-21.0%	$15.7M	N/A
Operating Income	-$50.3M	-$59.9M+9.9%	-$66.5M-19.8%	-$55.5M+17.4%	-$67.2M-27.5%	-$52.7M+39.1%	-$86.6M-209.5%	-$28.0M+32.5%	-$41.5M+24.1%	-$54.7M+31.0%	-$79.3M+37.2%	-$126.3M-24.9%	-$101.1M-82.3%	-$55.5M	N/A	N/A
Interest Expense	$9.4M	$8.7M+11.9%	$7.8M+48.2%	$5.2M-13.6%	$6.1M+21.1%	$5.0M-41.4%	$8.5M+187.2%	$3.0M-69.9%	$9.9M+78.0%	$5.5M+45.2%	$3.8M-8.1%	$4.2M+317.0%	$996K+18.3%	$842K-93.7%	$13.4M	N/A
Income Tax	N/A	-$537K	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	N/A
Net Income	-$37.7M	-$60.2M+28.2%	-$83.8M-33.8%	-$62.6M+40.4%	-$105.0M-158.6%	$179.1M	N/A	-$20.8M+41.9%	-$35.8M+51.1%	-$73.1M+8.8%	-$80.2M+30.1%	-$114.7M+15.4%	-$135.6M-106.2%	-$65.8M	N/A	N/A
EPS (Diluted)	—	-$0.04+42.9%	-$0.07-16.7%	-$0.06+40.0%	-$0.10-66.7%	-$0.06+91.8%	-$0.73-1725.0%	-$0.04	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$807K+63.4%	$494K-26.5%	$672K+236.0%	$200K+52.7%	$131K-65.1%	$375K+62.3%	$231K-35.3%	$357K
R&D Expenses	$5.7M+17.4%	$4.9M-12.5%	$5.6M-25.4%	$7.5M+0.3%	$7.4M-11.0%	$8.4M-20.6%	$10.5M+29.4%	$8.1M
SG&A Expenses	$6.7M+2.6%	$6.5M-24.2%	$8.6M+22.0%	$7.1M-5.5%	$7.5M-19.9%	$9.3M+13.7%	$8.2M+16.8%	$7.0M
Operating Income	-$11.6M-6.5%	-$10.9M+19.3%	-$13.5M+5.7%	-$14.3M+3.1%	-$14.8M+14.6%	-$17.3M+6.4%	-$18.5M-25.0%	-$14.8M
Interest Expense	$1.8M-22.9%	$2.3M-11.3%	$2.6M+1.0%	$2.6M+43.5%	$1.8M+14.0%	$1.6M-35.6%	$2.5M+19.6%	$2.1M
Net Income	-$9.2M-200.5%	-$3.1M-321.1%	$1.4M+105.2%	-$26.8M-74.5%	-$15.4M+20.5%	-$19.3M+31.5%	-$28.2M-45.7%	-$19.4M
EPS (Diluted)	-$0.01	$0.00	N/A	-$0.02-100.0%	-$0.010.0%	-$0.01	N/A	-$0.02

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

NWBO Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NWBO annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$81.3M+204.1%	$26.7M-4.1%	$27.9M-11.0%	$31.3M-22.0%	$40.2M+22.1%	$32.9M+209.1%	$10.6M-56.9%	$24.7M-49.6%	$48.9M-7.6%	$52.9M-25.3%	$70.8M+25.4%	$56.5M+200.6%	$18.8M+148.1%	$7.6M+3470.8%	$212K
Current Assets	$5.5M+35.8%	$4.1M-1.5%	$4.1M-56.2%	$9.4M-45.5%	$17.3M+11.5%	$15.5M+384.7%	$3.2M-86.6%	$23.8M+1597.4%	$1.4M-82.2%	$7.9M-67.3%	$24.1M+64.6%	$14.6M-21.5%	$18.6M+150.0%	$7.5M+6220.3%	$118K
Cash & Equivalents	$3.0M+39.8%	$2.2M+2.3%	$2.1M-69.5%	$7.0M-54.1%	$15.2M+51.9%	$10.0M+2583.6%	$372K-98.3%	$22.2M+18894.9%	$117K-98.3%	$6.9M-68.5%	$21.8M+62.9%	$13.4M-27.6%	$18.5M+151.8%	$7.3M+30508.3%	$24K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Goodwill	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$128.9M+6.3%	$121.2M+29.5%	$93.6M-41.3%	$159.4M-2.9%	$164.2M-58.5%	$395.8M+610.7%	$55.7M-22.5%	$71.8M-38.2%	$116.2M+46.4%	$79.4M+5.2%	$75.5M-17.5%	$91.5M+219.8%	$28.6M+21.0%	$23.6M-54.9%	$52.4M
Current Liabilities	$91.7M+34.3%	$68.3M+51.0%	$45.2M-64.1%	$126.0M-5.8%	$133.8M-65.0%	$382.4M+765.3%	$44.2M-36.7%	$69.8M-20.3%	$87.7M+14.8%	$76.4M+17.7%	$64.9M-13.4%	$75.0M+281.0%	$19.7M+83.3%	$10.7M-78.8%	$50.8M
Long-Term Debt	$60.0M-4.2%	$62.7M+53.6%	$40.8M+89.5%	$21.5M-33.5%	$32.4M+119.3%	$14.8M+16.1%	$12.7M-24.3%	$16.8M-46.6%	$31.4M-0.9%	$31.7M+39.0%	$22.8M	N/A	N/A	N/A	N/A
Total Equity	-$60.3M+36.2%	-$94.5M-43.7%	-$65.8M+48.7%	-$128.1M-3.3%	-$124.0M+65.8%	-$362.9M-705.6%	-$45.1M+6.4%	-$48.1M+28.5%	-$67.3M-154.1%	-$26.5M-466.7%	-$4.7M+86.7%	-$35.0M-256.8%	-$9.8M+38.9%	-$16.1M+69.2%	-$52.2M
Retained Earnings	-$1.5B-4.2%	-$1.4B-6.2%	-$1.4B-4.8%	-$1.3B-8.8%	-$1.2B+13.1%	-$1.4B-63.0%	-$841.4M-2.1%	-$824.4M-4.5%	-$788.6M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$75.9M-5.1%	$80.1M-1.5%	$81.3M+165.6%	$30.6M+3.6%	$29.5M+7.4%	$27.5M+2.9%	$26.7M-8.8%	$29.3M
Current Assets	$2.6M-58.5%	$6.2M+12.4%	$5.5M-23.4%	$7.2M+16.9%	$6.2M+31.3%	$4.7M+15.4%	$4.1M-21.8%	$5.2M
Cash & Equivalents	$595K-66.7%	$1.8M-41.3%	$3.0M-33.3%	$4.6M+5.7%	$4.3M+55.3%	$2.8M+27.8%	$2.2M-26.0%	$2.9M
Goodwill	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K0.0%	$626K
Total Liabilities	$110.7M-6.3%	$118.1M-8.3%	$128.9M-7.5%	$139.3M+7.2%	$129.9M+2.3%	$127.0M+4.8%	$121.2M+10.8%	$109.4M
Current Liabilities	$73.4M-11.6%	$83.0M-9.5%	$91.7M+4.3%	$87.9M+4.7%	$83.9M+1.0%	$83.1M+21.7%	$68.3M+14.6%	$59.6M
Long-Term Debt	$52.0M-12.5%	$59.4M-1.0%	$60.0M-16.8%	$72.2M+11.5%	$64.7M+0.9%	$64.1M+2.3%	$62.7M+17.7%	$53.3M
Total Equity	-$45.2M+10.6%	-$50.5M+16.2%	-$60.3M+44.5%	-$108.6M-8.2%	-$100.4M-0.9%	-$99.5M-5.3%	-$94.5M-17.9%	-$80.1M
Retained Earnings	-$1.5B-0.6%	-$1.5B-0.2%	-$1.5B+0.1%	-$1.5B-1.8%	-$1.5B-1.1%	-$1.5B-1.3%	-$1.4B-2.0%	-$1.4B

Not reported in any period shown, so not listed: Inventory.

NWBO Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

NWBO annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$48.3M	-$44.8M+21.5%	-$57.0M-6.3%	-$53.6M-1.6%	-$52.8M-37.8%	-$38.3M-19.3%	-$32.1M-0.7%	-$31.9M+7.9%	-$34.6M+5.2%	-$36.5M+34.4%	-$55.7M+29.2%	-$78.6M-44.0%	-$54.6M-44.4%	-$37.8M-66.1%	-$22.8M	N/A
Capital Expenditures	$1.4M	$1.5M+48.3%	$1.0M	N/A	N/A	N/A	N/A	$171K	N/A	N/A	N/A	N/A	N/A	-$1K-96.8%	$31K-36.7%	$49K
Free Cash Flow	-$49.8M	-$46.3M+20.3%	-$58.0M	N/A	N/A	N/A	N/A	-$32.0M	N/A	N/A	N/A	N/A	N/A	-$37.8M-65.9%	-$22.8M	N/A
Investing Cash Flow	-$1.7M	-$1.8M-79.0%	-$1.0M+70.5%	-$3.4M-18.4%	-$2.9M+51.8%	-$6.0M+26.1%	-$8.1M-2161.7%	-$360K-100.8%	$45.4M+21316.0%	$212K+104.3%	-$4.9M+26.8%	-$6.8M+81.4%	-$36.4M-3635300.0%	$1K+103.2%	-$31K+36.7%	-$49K
Financing Cash Flow	$41.7M	$49.3M-13.1%	$56.8M+7.6%	$52.8M+25.7%	$42.0M-12.8%	$48.1M-8.7%	$52.7M+429.5%	$10.0M+26.4%	$7.9M-77.0%	$34.3M-10.5%	$38.3M-59.3%	$94.2M+9.8%	$85.8M+75.3%	$49.0M+62.4%	$30.1M	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0-100.0%	$240K	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$7.2M+42.7%	-$12.5M+15.3%	-$14.8M-6.3%	-$13.9M-107.7%	-$6.7M+29.0%	-$9.4M+53.3%	-$20.2M-145.1%	-$8.2M
Capital Expenditures	$198K+53.5%	$129K-85.7%	$905K+348.0%	$202K-33.6%	$304K+226.9%	$93K+19.2%	$78K-55.7%	$176K
Free Cash Flow	-$7.4M+41.7%	-$12.6M+19.3%	-$15.7M-11.2%	-$14.1M-101.6%	-$7.0M+26.5%	-$9.5M+53.1%	-$20.3M-140.9%	-$8.4M
Investing Cash Flow	-$198K-53.5%	-$129K+85.7%	-$905K-76.4%	-$513K-68.8%	-$304K-226.9%	-$93K-19.2%	-$78K+55.7%	-$176K
Financing Cash Flow	$7.4M-19.9%	$9.2M-32.2%	$13.6M+17.6%	$11.6M-7.1%	$12.4M+6.1%	$11.7M-26.4%	$15.9M+37.2%	$11.6M

Not reported in any period shown, so not listed: Dividends Paid.

NWBO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

NWBO annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%0.0pp	100.0%0.0pp	100.0%
Operating Margin	-4347.9%	-4812.4%	-2873.1%	-3991.7%	-5244.0%	-6708.4%	-1161.0%	-10068.2%	-16273.2%	-12723.3%	-7261.9%	-6956.2%	-6857.1%	N/A	N/A
Net Margin	-4365.9%	-6062.1%	-3240.1%	-6240.8%	17823.5%	N/A	-863.6%	-8687.9%	-21768.8%	-12875.4%	-6598.1%	-9328.3%	-8132.1%	N/A	N/A
Return on Assets	-74.0%+239.4pp	-313.4%-88.8pp	-224.7%+110.7pp	-335.3%-781.4pp	446.0%	N/A	-195.6%-50.4pp	-145.1%+4.4pp	-149.6%+2.1pp	-151.6%+10.5pp	-162.1%+78.2pp	-240.3%+110.0pp	-350.2%	N/A	N/A
Current Ratio	0.060.0x	0.060.0x	0.090.0x	0.07-0.1x	0.13+0.1x	0.040.0x	0.07-0.3x	0.34+0.3x	0.02-0.1x	0.10-0.3x	0.37+0.2x	0.20-0.8x	0.95+0.3x	0.69+0.7x	0.00
FCF Margin	-3357.5%	-4199.1%	N/A	N/A	N/A	N/A	-1329.0%	N/A	N/A	N/A	N/A	N/A	-4672.6%	-2951.4%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Margin	-1438.0%	-2206.5%	-2009.5%	-7160.0%	-11281.7%	-4616.3%	-8008.2%	-4145.9%
Net Margin	-1142.6%	-621.3%	206.6%	-13414.5%	-11738.9%	-5158.1%	-12217.8%	-5426.9%
Return on Assets	-12.1%-8.3pp	-3.8%-5.5pp	1.7%+89.4pp	-87.6%-35.6pp	-52.0%+18.3pp	-70.3%+35.3pp	-105.6%-39.5pp	-66.1%
Current Ratio	0.040.0x	0.070.0x	0.060.0x	0.080.0x	0.070.0x	0.060.0x	0.060.0x	0.09
FCF Margin	-912.9%	-2558.3%	-2331.7%	-7047.5%	-5337.4%	-2536.3%	-8770.1%	-2355.5%

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$60.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Clinuvl Phrmaceu CLVLY

$362.5M

Cytodyn Inc CYDY

$328.7M

Nervgen Pharma Corp NGENF

$446.0M

Genus Plc GENSY

$2.0B

Hansa Medical AB HNSBF

$369.0M

Where Northwest Bio Ranks

Frequently Asked Questions

What is Northwest Bio's annual revenue?

Northwest Bio (NWBO) reported $1.4M in total revenue for fiscal year 2025. This represents a -0.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Northwest Bio's revenue growing?

Northwest Bio (NWBO) revenue declined by 0.3% year-over-year, from $1.4M to $1.4M in fiscal year 2025.

Is Northwest Bio profitable?

No, Northwest Bio (NWBO) reported a net income of -$60.2M in fiscal year 2025.

What is Northwest Bio's EBITDA?

Northwest Bio (NWBO) had EBITDA of -$57.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Northwest Bio have?

As of fiscal year 2025, Northwest Bio (NWBO) had $3.0M in cash and equivalents against $60.0M in long-term debt.

What is Northwest Bio's free cash flow?

Northwest Bio (NWBO) recorded an outflow of $46.3M in free cash flow during fiscal year 2025. This represents a 20.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Northwest Bio's operating cash flow?

Northwest Bio (NWBO) recorded an outflow of $44.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Northwest Bio's total assets?

Northwest Bio (NWBO) had $81.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Northwest Bio's capital expenditures?

Northwest Bio (NWBO) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Northwest Bio spend on research and development?

Northwest Bio (NWBO) invested $28.8M in research and development during fiscal year 2025.

How many shares does Northwest Bio have outstanding?

Northwest Bio (NWBO) had 1.56B shares outstanding as of fiscal year 2025.

What is Northwest Bio's current ratio?

Northwest Bio (NWBO) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Northwest Bio's return on assets (ROA)?

Northwest Bio (NWBO) had a return on assets of -74.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Northwest Bio's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Northwest Bio (NWBO) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $44.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Northwest Bio's debt-to-equity ratio negative or not reported?

Northwest Bio (NWBO) has negative shareholder equity of -$60.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Northwest Bio's Altman Z-Score?

Northwest Bio (NWBO) has an Altman Z-Score of -28.20, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Northwest Bio's Piotroski F-Score?

Northwest Bio (NWBO) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Northwest Bio's earnings high quality?

Northwest Bio (NWBO) reported a net loss of $60.2M while operations used $44.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Northwest Bio cover its interest payments?

Northwest Bio (NWBO) reported an operating loss of $59.9M against $8.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.